Log in to your Inderes Free account to see all free content on this page.
Genmab
1,943 DKK +1.01%13 investors are following this company
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Revenue
-
EBIT %
-
P/E
29.16
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GMAB
Daily low / high price
1,918 / 1,953
DKK
Market cap
128.5B DKK
Turnover
192.2M DKK
Volume
99K
Financial calendar
Interim report
08.08.2024
Interim report
06.11.2024
ShowingAll content types
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Completion of Share Buy-back Program
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio